{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:51Z","timestamp":1785797031790,"version":"3.56.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Low-molecular-weight heparins are currently the recommended antithrombotic therapy for treatment and prevention of malignancy-related venous thromboembolism. Currently, the evidence evaluating direct oral anticoagulants versus low-molecular-weight heparins or a vitamin K antagonist in cancer patients with hematologic malignancies is limited. We evaluated the safety and efficacy of direct oral anticoagulants for venous thromboembolism treatment or stroke prevention for non-valvular atrial fibrillation in patients with hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective evaluation of adult patients with hematologic malignancies who received at least one dose of the Food and Drug Administration-approved direct oral anticoagulant for venous thromboembolism treatment or stroke prevention. We determined the frequency of major bleeding events, non-major bleeding events, stroke, systemic embolism, appropriateness of initial direct oral anticoagulant doses, holding practices prior to procedures, and the rate of all-cause mortality. An analysis was also performed to compare the incidence of bleeding between patients with a history of hematopoietic stem cell transplant to non-transplant patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 103 patients were identified, with the majority of patients receiving rivaroxaban for venous thromboembolism treatment. Major bleeding events occurred in four patients and no fatal bleeding events occurred. Non-major bleeding occurred in 29 patients, most commonly epistaxis and bruising. Two patients experienced a systemic embolism while on direct oral anticoagulant therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Direct oral anticoagulants may be a safe and effective alternative for anticoagulation therapy in patients with hematologic malignancies. However, larger prospective studies comparing direct oral anticoagulants to low-molecular-weight heparins or vitamin K antagonists are warranted to compare efficacy and safety outcomes in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219848810","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T01:59:55Z","timestamp":1559181595000},"page":"351-360","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of direct oral anticoagulants for venous thromboembolism and stroke prophylaxis in patients with hematologic malignancies"],"prefix":"10.1177","volume":"26","author":[{"given":"Stephanie","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health, San Diego, CA, USA"},{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Medicine, UC San Diego Health, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8805-3734","authenticated-orcid":false,"given":"Ila M","family":"Saunders","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UC San Diego Health, San Diego, CA, USA"},{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"bibr1-1078155219848810","doi-asserted-by":"crossref","unstructured":"Ravikumar R, Lim CS and Davies AH. The role of new oral Anticoagulants (NOACs) in cancer patients.\n                      Adv Exp Med Biol\n                      2017; 906: 137\u2013148.","DOI":"10.1007\/5584_2016_112"},{"key":"bibr2-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313"},{"key":"bibr3-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1118"},{"key":"bibr4-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0402"},{"key":"bibr5-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"bibr6-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948"},{"key":"bibr7-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"bibr8-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"bibr9-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14219"},{"key":"bibr10-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24526"},{"key":"bibr11-1078155219848810","first-page":"94","volume":"39","author":"Franchini M","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"bibr12-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504741"},{"key":"bibr13-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1177\/2042098617719815"},{"key":"bibr14-1078155219848810","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (package insert). Ridgefield: Boehringer Ingelheim Pharmaceuticals Inc, 2017."},{"key":"bibr15-1078155219848810","unstructured":"Janssen Pharmaceuticals, Inc. Xarelto (package insert). Titusville: Janssen Pharmaceuticals, Inc, 2017."},{"key":"bibr16-1078155219848810","unstructured":"Pfizer Inc. Eliquis (package insert). New York: Pfizer Inc, 2017."},{"key":"bibr17-1078155219848810","unstructured":"Daiichi Sankyo Co. Savaysa (package insert). Basking Ridge: Daiichi Sankyo Co, 2017."},{"key":"bibr18-1078155219848810","unstructured":"Drug Interactions & Labeling. Drug development and drug interactions: table of substrates, inhibitors and inducers, www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm (accessed 10 December 2018)."},{"key":"bibr19-1078155219848810","unstructured":"Hansten PD and Horn JR.\n                      The top 100 drug interactions: a guide to patient management\n                      . 2018th ed. Freeland: H & H Publications."},{"key":"bibr20-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12873"},{"key":"bibr21-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"bibr22-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"bibr23-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-017-1534-9"},{"key":"bibr24-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181faa0f2"},{"key":"bibr25-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2004.022178"},{"key":"bibr26-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-017-0137-1"},{"key":"bibr27-1078155219848810","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130040"},{"key":"bibr28-1078155219848810","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.024"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219848810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219848810","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219848810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:09Z","timestamp":1777688469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219848810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/1078155219848810"],"URL":"https:\/\/doi.org\/10.1177\/1078155219848810","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,29]]}}}